Heyman Tomas J. — SEC Form 4 filings
SEC reporting owner CIK 1814673. 9 Form 4 filings on record with FilingPulse; latest filed 2026-05-29.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-06-04 to 2026-05-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 4,544 shares, $201,254 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 16.
- Largest priced transaction: sale of 4,544 shares @ $44.29 ($201,254) in EXELIXIS, INC., filed 2025-05-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| EXELIXIS, INC. (EXEL) | Director | 4 | — | 1 leg · 4,544 sh · $201,254 | 3 |
| Akero Therapeutics, Inc. (AKRO) | Director | 3 | — | — | 7 |
| OptiNose, Inc. (OPTN) | Director | 2 | — | — | 6 |
Form 4 filings — Heyman Tomas J.
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-05-29 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 8,367 @ $0 | EDGAR |
| 2025-12-09 | 4 | Akero Therapeutics, Inc. (AKRO) | Disposition to issuer (D): 9,398 · Disposition to issuer (D): 26,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 13,000 (derivative) | EDGAR |
| 2025-06-05 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 9,398 @ $0 | EDGAR |
| 2025-05-30 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 9,812 @ $0 | EDGAR |
| 2025-05-22 | 4 | EXELIXIS, INC. (EXEL) | Sale (S): 4,544 @ $44.29 | EDGAR |
| 2025-05-21 | 4 | OptiNose, Inc. (OPTN) | Disposition to issuer (D): 5,000 (derivative) · Disposition to issuer (D): 3,566 (derivative) · Disposition to issuer (D): 2,133 (derivative) · Disposition to issuer (D): 962 (derivative) · Disposition to issuer (D): 1,925 (derivative) | EDGAR |
| 2024-06-11 | 4 | Akero Therapeutics, Inc. (AKRO) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | OptiNose, Inc. (OPTN) | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | EXELIXIS, INC. (EXEL) | Grant/award (A): 18,838 @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1814673 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →